Becton, Dickinson and Company $BDX Stock Position Lifted by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 12.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,922 shares of the medical instruments supplier’s stock after acquiring an additional 2,811 shares during the quarter. Pinnacle Associates Ltd.’s holdings in Becton, Dickinson and Company were worth $4,640,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its stake in Becton, Dickinson and Company by 18.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 80,374 shares of the medical instruments supplier’s stock valued at $14,387,000 after purchasing an additional 12,798 shares during the last quarter. Integrated Advisors Network LLC acquired a new stake in Becton, Dickinson and Company in the third quarter valued at approximately $312,000. Robeco Institutional Asset Management B.V. boosted its position in Becton, Dickinson and Company by 271.8% in the third quarter. Robeco Institutional Asset Management B.V. now owns 159,520 shares of the medical instruments supplier’s stock valued at $28,554,000 after buying an additional 116,612 shares in the last quarter. Wagner Wealth Management Corp bought a new stake in shares of Becton, Dickinson and Company during the third quarter worth $473,000. Finally, Revisor Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 4.6% during the third quarter. Revisor Wealth Management LLC now owns 13,066 shares of the medical instruments supplier’s stock worth $2,339,000 after buying an additional 574 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 3.0%

BDX opened at $200.21 on Friday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $200.47. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The firm has a market capitalization of $55.16 billion, a price-to-earnings ratio of 60.30, a PEG ratio of 13.10 and a beta of 0.21. The company’s 50 day moving average price is $185.10 and its two-hundred day moving average price is $164.86.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were paid a $1.05 dividend. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BDX shares. Wolfe Research began coverage on shares of Becton, Dickinson and Company in a report on Tuesday. They set an “outperform” rating for the company. Bank of America raised their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Monday, August 31st. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a report on Monday, July 6th. Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus target price of $185.07.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael Feld sold 165 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 6,906 shares of company stock worth $1,265,855 over the last three months. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.